Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2023 Jan 4:13:1033513.
doi: 10.3389/fimmu.2022.1033513. eCollection 2022.

Case report: Pneumocystis jirovecii pneumonia in a severe case of Aicardi-Goutières syndrome with an IFIH1 gain-of-function mutation mimicking combined immunodeficiency

Mojca Železnik  1 , Aneta Soltirovska Šalamon  1 , Maruša Debeljak  2 , Aleš Goropevšek  3 , Nataša Šuštar  4 , Damjana Ključevšek  5 , Alojz Ihan  6 , Tadej Avčin  7   8
Affiliations
Case Reports

Case report: Pneumocystis jirovecii pneumonia in a severe case of Aicardi-Goutières syndrome with an IFIH1 gain-of-function mutation mimicking combined immunodeficiency

Mojca Železnik et al. Front Immunol. .

Abstract

Aicardi-Goutières syndrome (AGS) is a genetically determined early-onset progressive encephalopathy caused by mutations leading to overexpression of type I interferon (IFN) and resulting in various clinical phenotypes. A gain-of-function (GOF) mutation in the IFIH1 gene is associated with robust production of type I IFN and activation of the Janus kinase (JAK) signal transducer and activator of the transcription (STAT) pathway, which can cause AGS type 7. We detail the clinical case of an infant who initially presented with Pneumocystis jirovecii pneumonia (PCP), had recurrent respiratory infections, and was later treated with a JAK inhibitor, baricitinib, because of a genetically confirmed GOF mutation in the IFIH1 gene. This spectrum of IFIH1 GOF mutations with overlapping features of hyperinflammation and severe opportunistic infection, which mimics combined immunodeficiency (CID), has not been described before. In this case, therapy with baricitinib effectively blocked IFN-α activation and reduced STAT1 signaling but had no effect on the progression of the neurological disease.

Keywords: Aicardi–Goutières syndrome (AGS); IFIH1 gene; Janus kinase inhibitor; combined immune deficiency; interferonopathy.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
Initial brain MRI scans (T2 sagittal and axial plane). (A) Normal thickness of pons and midbrain. (A, B) Higher T2 signal of the frontal white matter.
Figure 2
Figure 2
(A): Total STAT1 levels in CD4+ T lymphocytes from the patient on indicated time points and healthy controls. (B) Phosphorylated STAT1 (pSTAT1) levels in unstimulated whole-blood CD4+ T lymphocytes and on interferon (IFN)-α induction. (C) Basal (unstimulated) pSTAT1 levels and pSTAT1 levels on stimulation with IFN-α for 15 minutes in CD4+ T lymphocytes from the patient before treatment and after 3 months of baricitinib, and from healthy controls. Values in (A) and (C) for healthy controls (n=3) are the mean ± SD. MFI, median fluorescence intensity; HC, healthy controls.
Figure 3
Figure 3
(A) Follow-up brain MRI scans (T2 sagittal and axial plane) after 1 year: severe atrophy of midbrain compared with initial MRI. (B) Severe reduction of brain volume and abnormal signal of the white matter—leucoencephalopathy.
See this image and copyright information in PMC

References

    1. Aicardi J, Goutières F. A progressive familial encephalopathy in infancy with calcifications of the basal ganglia and chronic cerebrospinal fluid lymphocytosis. Ann Neurol (1984) 15:49–54. doi: 10.1002/ana.410150109 - DOI - PubMed
    1. Oda H, Nakagawa K, Abe J, Awaya T, Funabiki M, Hijikata A, et al. Aicardi-goutières syndrome is caused by IFIH1 mutations. Am J Hum Genet (2014) 95(1):121–5. doi: 10.1016/j.ajhg.2014.06.007 - DOI - PMC - PubMed
    1. Crow YJ, Zaki MS, Abdel-Hamid M, Boesp O, Cordeiro NJV, Gleeson JG, et al. Mutations in ADAR1 , IFIH1 , and RNASEH2B presenting as spastic paraplegia. Neuropediatrics (2014) 45(6):386–93. doi: 10.1055/s-0034-1389161 - DOI - PubMed
    1. Crow YJ, Chase DS, Lowenstein Schmidt J, Szynkiewicz M, Forte G, Gornall HL, et al. Characterization of human disease phenotypes associated with mutations in TREX1 , RNASEH2A, RNASEH2B, RNASEH2C, SAMHD1. ADAR, and IFIH1. Am J Med Genet Part A (2015) 167A(2):296–312. doi: 10.1002/ajmg.a.36887 - DOI - PMC - PubMed
    1. Rice GI, Del Toro Duany Y, Jenkinson EM, Forte GMA, Anderson BH, Ariaudo G, et al. Gain-of-function mutations in IFIH1 cause a spectrum of human disease phenotypes associated with upregulated type i interferon signaling. Nat Genet (2014) 46(5):503–9. doi: 10.1038/ng.2933 - DOI - PMC - PubMed

Publication types

MeSH terms

Supplementary concepts